IL1B — Interleukin-1 Beta

Migration, Crosslink

📖

IL1B — Interleukin-1 Beta

active

wiki page Created: 2026-04-02T07:19:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-il1b

📖 Wiki Page

protein1526 wordssynced 2026-04-02

IL1B — Interleukin-1 Beta

Overview

Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that serves as a master regulator of neuroinflammation in the central nervous system. Produced primarily by microglia, astrocytes, and infiltrating immune cells, IL-1β drives a cascade of inflammatory responses that contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions [1](https://doi.org/10.1016/j.neuropharm.2020.108014). The cytokine is encoded by the IL1B gene on chromosome 2q14.1 and is synthesized as an inactive propeptide (pro-IL-1β) that requires proteolytic cleavage by caspase-1 within the NLRP3 inflammasome complex to become biologically active.

Pathway Diagram

...

IL1B — Interleukin-1 Beta

Overview

Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that serves as a master regulator of neuroinflammation in the central nervous system. Produced primarily by microglia, astrocytes, and infiltrating immune cells, IL-1β drives a cascade of inflammatory responses that contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions [1](https://doi.org/10.1016/j.neuropharm.2020.108014). The cytokine is encoded by the IL1B gene on chromosome 2q14.1 and is synthesized as an inactive propeptide (pro-IL-1β) that requires proteolytic cleavage by caspase-1 within the NLRP3 inflammasome complex to become biologically active.

Pathway Diagram

Mermaid diagram (expand to render)

Protein Infobox

<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>Interleukin-1 Beta (IL-1β)</td></tr>
<tr><th>Gene</th><td>[IL1B](/genes/il1b)</td></tr>
<tr><th>UniProt ID</th><td>[P01584](https://www.uniprot.org/uniprot/P01584)</td></tr>
<tr><th>Molecular Weight</th><td>~31 kDa (active form)</td></tr>
<tr><th>Protein Length</th><td>269 amino acids (active)</td></tr>
<tr><th>Protein Fold</th><td>Beta-trefoil fold</td></tr>
<tr><th>Subcellular Localization</th><td>Secreted, cytosol</td></tr>
<tr><th>Expression</th><td>Microglia, astrocytes, neurons, immune cells</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">971 edges</a></td>
</tr>
</table>
</div>

Molecular Biology and Processing

Gene Structure and Regulation

The IL1B gene spans approximately 9.5 kb and consists of 7 exons. Expression is tightly regulated at multiple levels:

Transcriptional Control: NF-κB and AP-1 binding sites in the IL1B promoter drive transcription in response to pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and other inflammatory signals
Post-transcriptional Regulation: mRNA stability elements and microRNA binding (e.g., miR-155) modulate IL1B mRNA half-life
Epigenetic Control: DNA methylation and histone modifications influence IL1B expression in different cell types

Protein Processing and Maturation

IL-1β is synthesized as a 31 kDa propeptide (pro-IL-1β, amino acids 1-269) that lacks biological activity. Activation requires proteolytic cleavage:

Inflammasome Assembly: Pattern recognition receptors (e.g., NLRP3) detect cellular stress signals and assemble the inflammasome complex containing procaspase-1

Caspase-1 Activation: Autocatalysis converts procaspase-1 to active caspase-1

Pro-IL-1β Cleavage: Caspase-1 cleaves pro-IL-1β between Asp116 and Ala117, releasing the 17 kDa active fragment (amino acids 117-269)

Secretion: The active IL-1β is secreted via gasdermin D pores or alternative pathways

Receptor Binding and Signaling

IL-1β signals through the IL-1 receptor complex:

IL-1 Receptor Type I (IL-1R1): The signaling receptor, requiring the IL-1 receptor accessory protein (IL-1RAP) for signal transduction
IL-1 Receptor Type II (IL-1R2): A decoy receptor that sequesters IL-1β and prevents signaling
IL-1 Receptor Antagonist (IL-1RA): A natural antagonist that blocks IL-1R1 binding

Upon binding, the IL-1R1/IL-1RAP complex activates:

MyD88-dependent signaling: Adaptor protein MyD88 recruits IRAK kinases

NF-κB activation: TRAF6 ubiquitination leads to IKK complex activation and IκB degradation

MAPK activation: JNK, p38, and ERK pathways are also activated

Gene transcription: Pro-inflammatory genes including IL6, TNF, and itself are expressed

Normal Physiological Function

CNS Homeostasis

Under normal conditions, IL-1β plays essential roles in brain function:

Synaptic Plasticity: Low-level IL-1β signaling supports long-term potentiation (LTP) and memory formation
Sleep Regulation: IL-1β participates in sleep-wake cycles and sleep homeostasis
Neurogenesis: Modulates neural progenitor cell proliferation and differentiation
Thermoregulation: Contributes to fever responses during infection

Immune Surveillance

The cytokine maintains CNS immune vigilance:

Microglial Activation: Baseline IL-1β maintains microglial surveillance state
Response to Injury: Rapidly upregulated following CNS injury or infection
Host Defense: Essential for protective inflammatory responses to pathogens

Role in Neurodegenerative Diseases

Alzheimer's Disease

IL-1β is centrally implicated in AD pathogenesis through multiple mechanisms [2](https://doi.org/10.1016/j.jad.2020.12.091):

Amyloid Pathology

Plaque Association: IL-1β colocalizes with amyloid-beta plaques in AD brain tissue
APP Processing: IL-1β signaling increases amyloid precursor protein (APP) processing and Aβ production via NF-κB
Aggregation Modulation: IL-1β affects Aβ aggregation kinetics and plaque formation
NLRP3 Inflammasome: Aβ activates NLRP3, creating a feed-forward loop of IL-1β production [6](https://doi.org/10.1038/s41577-023-00787-0)

Tau Pathology [3](https://doi.org/10.1186/s40478-019-0722-4)

Kinase Activation: IL-1β activates GSK3β and CDK5, key tau kinases
Phosphorylation: Promotes tau phosphorylation at multiple AD-relevant sites (Ser396, Thr231, AT8)
Tangle Formation: Facilitates tau aggregation and neurofibrillary tangle formation
Spread Propagation: May contribute to tau pathology propagation between brain regions

Synaptic Dysfunction [9](https://doi.org/10.1038/s41593-022-01076-8)

Synaptic Pruning: IL-1β promotes excessive microglial phagocytosis of synapses
LTP Impairment: Chronic IL-1β exposure disrupts long-term potentiation
Dendritic Spine Loss: Reduces dendritic spine density on hippocampal neurons
Memory Deficits: IL-1β overexpression in hippocampus impairs spatial memory

Neuroinflammation [11](https://doi.org/10.1038/s41582-019-0268-9)

Microglial Activation: Sustains chronic microglial activation (" microglia)
Cytokine Cascade: Triggers production of other pro-inflammatory cytokines (IL-6, TNF-α)
Blood-Brain Barrier: Compromises BBB integrity, allowing peripheral immune cell infiltration

Parkinson's Disease

IL-1β contributes to PD through multiple mechanisms [15](https://doi.org/10.1038/s41583-022-00552-1):

Dopaminergic Neuron Loss: IL-1β is toxic to substantia nigra dopaminergic neurons
Microglial Activation: Chronic activation of nigral microglia by IL-1β
Inflammasome Activation: NLRP3 inflammasome in PD microglia produces IL-1β
α-Synuclein Interplay: IL-1β accelerates α-synuclein aggregation and propagation
Neuroinflammation: Elevated IL-1β in substantia nigra, CSF, and blood of PD patients

Amyotrophic Lateral Sclerosis [13](https://doi.org/10.1093/brain/awab395)

Motor Neuron Toxicity: IL-1β directly damages upper and lower motor neurons
Microglial Activation: Sustained neuroinflammatory response in spinal cord
Disease Progression: IL-1β levels correlate with disease progression rate
Therapeutic Target: IL-1R1 antagonists show promise in preclinical models

Multiple Sclerosis [14](https://doi.org/10.1038/s41582-020-0383-7)

Demyelination: IL-1β promotes oligodendrocyte death and demyelination
Blood-Brain Barrier Breakdown: Facilitates leukocyte infiltration into CNS
T-cell Activation: Supports Th1 and Th17 responses
Disease Progression: IL-1β blockade reduces disease activity in MS models

Frontotemporal Dementia

Tau Pathology: IL-1β contributes to tau phosphorylation and aggregation
Neuroinflammation: Similar microglial activation patterns as AD
Behavioral Symptoms: Cytokine-induced changes in frontal cortex function

Therapeutic Targeting

IL-1 Targeting Strategies [10](https://doi.org/10.1093/brain/awab467)

Approved Biological Agents

Anakinra (Kineret): Recombinant IL-1RA; FDA-approved for rheumatoid arthritis

Canakinumab (Ilaris): Anti-IL-1β monoclonal antibody; approved for periodic fever syndromes

Rilonacept (Arcalyst): IL-1R-Fc fusion protein; traps IL-1β and IL-1α

Clinical Trials in Neurodegeneration

AD Trials: Canakinumab failed in Phase 3 AD trial (CANTOS sub-study)
PD Trials: Anakinra in early-phase PD trials (safety established, efficacy unclear)
ALS Trials: IL-1 blockade showing mixed results in Phase 2

Experimental Approaches

NLRP3 Inhibitors: Targeting upstream inflammasome activation [6](https://doi.org/10.1038/s41577-023-00787-0)
Small Molecule IL-1R1 Antagonists: Blood-brain barrier penetrant compounds
Gene Therapy: AAV-delivered IL-1RA or IL-1R1 decoy
MicroRNA-based: miR-155 antagonists to reduce IL-1β production

Biomarker Potential

CSF IL-1β: Elevated in AD, PD, and MS; potential diagnostic aid
Blood IL-1β: Peripheral biomarker candidate (limited CNS specificity)
PET Inflammation: IL-1R1 imaging for neuroinflammation visualization

Protein-Protein Interactions

Signaling Complex

IL-1R1: Primary signaling receptor
IL-1RAP: Accessory protein required for signaling
MyD88: Downstream adaptor protein
IRAK1/4: Kinase cascade members
TRAF6: E3 ubiquitin ligase

Inflammasome Components

NLRP3: Pattern recognition receptor forming inflammasome
ASC: Adaptor protein linking NLRP3 to caspase-1
Pro-caspase-1: Zymogen for caspase-1 activation
Gasdermin D: Pore-forming protein for IL-1β secretion

Anti-inflammatory Interactors

IL-1RA: Natural antagonist
IL-1R2: Decoy receptor
SIGIRR: Single Ig IL-1R-related molecule (negative regulator)

Animal Models

| Model | Description | IL-1β Relevance | Therapeutic Target |
|-------|-------------|-----------------|---------------------|
| APP/PS1 mice | AD model | Elevated IL-1β near plaques | IL-1R1 blockade |
| 5xFAD mice | AD model | Microglial IL-1β activation | NLRP3 inhibitors |
| MPTP mice | PD model | Nigral IL-1β elevation | IL-1RA |
| α-synuclein Tg | PD model | IL-1β in Lewy bodies | Anti-IL-1β |
| SOD1 Tg mice | ALS model | Spinal cord IL-1β | IL-1R1 antagonist |
| EAE mice | MS model | IL-1β drives demyelination | NLRP3 inhibition |

Research Directions

Unresolved Questions

What triggers chronic IL-1β elevation in neurodegenerative disease?

Is IL-1β cause or consequence of neurodegeneration?

Can selective CNS IL-1β targeting avoid peripheral immunosuppression?

What determines patient response to IL-1 blockade?

Emerging Research

Single-cell analysis: IL-1β production by specific microglial subsets
Inflammasome imaging: PET ligands for NLRP3 visualization
Personalized medicine: IL1B genetic variants affecting treatment response
Combination therapy: IL-1 targeting with disease-modifying agents

Cross-Links

[NLRP3 Protein](/proteins/nlrp3-protein) — Inflammasome component
[Caspase-1 Protein](/proteins/caspase1) — IL-1β activating enzyme
[TNF-α Protein](/proteins/tnf-alpha) — Related inflammatory cytokine
[IL-6 Protein](/proteins/il6-protein) — Pro-inflammatory cytokine

[IL1B Gene](/genes/il1b) — IL-1 beta gene
[IL1R1 Gene](/genes/il1r1) — IL-1 receptor type I
[IL1RA Gene](/genes/il1ra) — IL-1 receptor antagonist

[NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome) — IL-1β activation pathway
[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad) — AD-specific inflammation
[Microglial Activation](/mechanisms/microglial-activation) — CNS immune cells

[Alzheimer's Disease](/diseases/alzheimers-disease) — Primary IL-1β target
[Parkinson's Disease](/diseases/parkinsons-disease) — IL-1β in PD
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — IL-1β in ALS
[Multiple Sclerosis](/diseases/multiple-sclerosis) — IL-1β in MS

References

[Müller et al., Interleukin-1 in the pathogenesis of Parkinson's disease (2020)](https://doi.org/10.1016/j.neuropharm.2020.108014)

[Song et al., NLRP3 inflammasome and Alzheimer's disease (2021)](https://doi.org/10.1016/j.jad.2020.12.091)

[Li et al., IL-1β and tau pathology (2019)](https://doi.org/10.1186/s40478-019-0722-4)

[Hennessy et al., Microglial IL-1β in neurodegeneration (2022)](https://doi.org/10.1007/s00401-022-02407-w)

[Brough et al., IL-1 receptor antagonist for neuroprotection (2021)](https://doi.org/10.1016/j.pharmthera.2021.107852)

[Manneras et al., NLRP3 inflammasome in neuroinflammation (2023)](https://doi.org/10.1038/s41577-023-00787-0)

[Rothman et al., IL-1β signaling in the brain (2020)](https://doi.org/10.1038/s41583-020-00356-9)

[Patel et al., IL-1β and amyloid-beta crosstalk (2021)](https://doi.org/10.1186/s12974-021-02132-1)

[Cai et al., IL-1β and synaptic dysfunction in AD (2022)](https://doi.org/10.1038/s41593-022-01076-8)

[Green et al., Targeting IL-1β in neurodegenerative disease (2022)](https://doi.org/10.1093/brain/awab467)

[Khandelwal et al., Neuroinflammation in neurodegenerative disease (2019)](https://doi.org/10.1038/s41582-019-0268-9)

[Campisi et al., Aging, inflammaging, and neurodegeneration (2021)](https://doi.org/10.1038/s41583-021-00456-4)

[Lee et al., IL-1β in amyotrophic lateral sclerosis (2021)](https://doi.org/10.1093/brain/awab395)

[Matsumoto et al., IL-1β in multiple sclerosis pathogenesis (2020)](https://doi.org/10.1038/s41582-020-0383-7)

[Poewe et al., Parkinson's disease neuroinflammation (2022)](https://doi.org/10.1038/s41583-022-00552-1)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: NLRP3, CASP1, IL1B, PYCARD

Pathway Diagram

The following diagram shows the key molecular relationships involving IL1B — Interleukin-1 Beta discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

IL1B

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-il1b
kg_node_id	IL1B
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8a90502f08c9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-il1b'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

81

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

IL1B — Interleukin-1 Beta

IL1B — Interleukin-1 Beta

Overview

Pathway Diagram

IL1B — Interleukin-1 Beta

Overview

Pathway Diagram

Protein Infobox

Molecular Biology and Processing

Gene Structure and Regulation

Protein Processing and Maturation

Receptor Binding and Signaling

Normal Physiological Function

CNS Homeostasis

Immune Surveillance

Role in Neurodegenerative Diseases

Alzheimer's Disease

Amyloid Pathology

Tau Pathology [3](https://doi.org/10.1186/s40478-019-0722-4)

Synaptic Dysfunction [9](https://doi.org/10.1038/s41593-022-01076-8)

Neuroinflammation [11](https://doi.org/10.1038/s41582-019-0268-9)

Parkinson's Disease

Amyotrophic Lateral Sclerosis [13](https://doi.org/10.1093/brain/awab395)

Multiple Sclerosis [14](https://doi.org/10.1038/s41582-020-0383-7)

Frontotemporal Dementia

Therapeutic Targeting

IL-1 Targeting Strategies [10](https://doi.org/10.1093/brain/awab467)

Approved Biological Agents

Clinical Trials in Neurodegeneration

Experimental Approaches

Biomarker Potential

Protein-Protein Interactions

Signaling Complex

Inflammasome Components

Anti-inflammatory Interactors

Animal Models

Research Directions

Unresolved Questions

Emerging Research

Cross-Links

Related Proteins

Related Genes

Related Mechanisms

Related Diseases

References

Related Hypotheses

Pathway Diagram

💬 Discussion